Current advancements and potential strategies in the development of MERS-CoV vaccines - PubMed
Review
Current advancements and potential strategies in the development of MERS-CoV vaccines
Naru Zhang et al. Expert Rev Vaccines. 2014 Jun.
Abstract
Middle East respiratory syndrome (MERS) is a newly emerging infectious disease caused by a novel coronavirus, MERS-coronavirus (MERS-CoV), a new member in the lineage C of β-coronavirus (β-CoV). The increased human cases and high mortality rate of MERS-CoV infection make it essential to develop safe and effective vaccines. In this review, the current advancements and potential strategies in the development of MERS vaccines, particularly subunit vaccines based on MERS-CoV spike (S) protein and its receptor-binding domain (RBD), are discussed. How to improve the efficacy of subunit vaccines through novel adjuvant formulations and routes of administration as well as currently available animal models for evaluating the in vivo efficacy of MERS-CoV vaccines are also addressed. Overall, these strategies may have important implications for the development of effective and safe vaccines for MERS-CoV in the future.
Keywords: MERS-CoV; Middle East respiratory syndrome; adjuvants; administration routes; coronavirus; receptor-binding domain; spike protein; subunit vaccines; vaccines.
Figures

Laboratory confirmed cases of human infection with MERS-coronavirus. The black columns indicate the total laboratory confirmed human cases infected with MERS-CoV, while the gray columns demonstrate the total deaths caused by MERS-CoV infection from September 2012 to the indicated date.

Genomic and schematic diagram of MERS-coronavirus structure. (A) MERS-CoV genomic structure. Viral genes, including ORF 1a, ORF 1b, S, 3, 4a, 4b, 5, E, M, 8b and N (GenBank accession number: JX869059) and their respective lengths, are indicated by rectangular boxes in the scheme. (B) Schematic diagram of MERS-CoV structure. MERS-CoV contains four structural proteins. The S protein is a type I transmembrane glycoprotein displayed on the surface of viral membrane as an oligomer. The E protein is also a transmembrane protein that forms an ion channel on the viral surface. The N protein plays an important role in encapsidating the genomic RNA and interacting with the membrane M protein and other N molecules.

Schematic diagrams of spike protein structures of representative coronaviruses. Schematic diagrams of the structures of S proteins of the previously identified coronaviruses NL63-CoV, MHV-CoV, SARS-CoV (A), and the newly emerged coronavirus MERS-CoV (B) are indicated. The S proteins contain S1 and S2 subunits, respectively, with RBDs located in the S1 region. RBMs are functional regions within RBDs for receptor recognition. Other functional domains, such as fusion peptide, HR1, HR2, transmembrane and cytoplasmic tail, contain variant lengths within different coronaviruses.

Crystal structures of SARS-CoV and MERS-CoV RBD and neutralizing epitopes on SARS-CoV RBD. (A) Crystal structure of SARS-CoV RBD complexed with its receptor ACE2 (blue) (PDB ID: 2AJF) [31]. (B) Neutralizing epitope for mAb m396 Fab on SARS-CoV RBD (PDB ID: 2DD8) [41]. SARS-CoV RBD is in black with RBM region in yellow. (C) Neutralizing epitope for mAb F26G19 Fab on SARS-CoV RBD (PDB ID: 3BGF) [40]. (D) Neutralizing epitope for mAb 80R scFv on SARS-CoV RBD (PDB ID: 2GHW) [42]. (E) Crystal structure of MERS-CoV RBD. The RBM is in yellow. (PDB ID: 4KQZ) [36]. (F) Crystal structure of MERS-CoV RBD (black) complexed with its receptor human DPP4 (blue) (PDB ID: 4KR0) [37].
Similar articles
-
Receptor-binding domain-based subunit vaccines against MERS-CoV.
Zhang N, Tang J, Lu L, Jiang S, Du L. Zhang N, et al. Virus Res. 2015 Apr 16;202:151-9. doi: 10.1016/j.virusres.2014.11.013. Epub 2014 Nov 20. Virus Res. 2015. PMID: 25445336 Free PMC article. Review.
-
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, Frieman MB. Coleman CM, et al. Vaccine. 2017 Mar 14;35(12):1586-1589. doi: 10.1016/j.vaccine.2017.02.012. Epub 2017 Feb 23. Vaccine. 2017. PMID: 28237499 Free PMC article.
-
Li E, Chi H, Huang P, Yan F, Zhang Y, Liu C, Wang Z, Li G, Zhang S, Mo R, Jin H, Wang H, Feng N, Wang J, Bi Y, Wang T, Sun W, Gao Y, Zhao Y, Yang S, Xia X. Li E, et al. Viruses. 2019 Aug 29;11(9):799. doi: 10.3390/v11090799. Viruses. 2019. PMID: 31470645 Free PMC article.
-
Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng CT, Zhou Y, Perlman S, Jiang S, Du L. Zhang N, et al. Cell Mol Immunol. 2016 Mar;13(2):180-90. doi: 10.1038/cmi.2015.03. Epub 2015 Feb 2. Cell Mol Immunol. 2016. PMID: 25640653 Free PMC article.
-
MERS-CoV spike protein: Targets for vaccines and therapeutics.
Wang Q, Wong G, Lu G, Yan J, Gao GF. Wang Q, et al. Antiviral Res. 2016 Sep;133:165-77. doi: 10.1016/j.antiviral.2016.07.015. Epub 2016 Jul 26. Antiviral Res. 2016. PMID: 27468951 Free PMC article. Review.
Cited by
-
SARS-CoV-2 vaccines: Lights and shadows.
Angeli F, Spanevello A, Reboldi G, Visca D, Verdecchia P. Angeli F, et al. Eur J Intern Med. 2021 Jun;88:1-8. doi: 10.1016/j.ejim.2021.04.019. Epub 2021 Apr 30. Eur J Intern Med. 2021. PMID: 33966930 Free PMC article. Review.
-
Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.
Pereira GJDS, Leão AHFF, Erustes AG, Morais IBM, Vrechi TAM, Zamarioli LDS, Pereira CAS, Marchioro LO, Sperandio LP, Lins ÍVF, Piacentini M, Fimia GM, Reckziegel P, Smaili SS, Bincoletto C. Pereira GJDS, et al. Int J Mol Sci. 2021 Apr 15;22(8):4067. doi: 10.3390/ijms22084067. Int J Mol Sci. 2021. PMID: 33920748 Free PMC article. Review.
-
Preventing drug-resistant tuberculosis transmission.
Koch A, Cox H. Koch A, et al. Lancet Infect Dis. 2020 Feb;20(2):157-158. doi: 10.1016/S1473-3099(19)30613-9. Epub 2019 Nov 26. Lancet Infect Dis. 2020. PMID: 31784368 No abstract available.
-
Noorabad Ghahroodi F, Khalili S, Rasaee MJ. Noorabad Ghahroodi F, et al. J Clin Lab Anal. 2022 May;36(5):e24328. doi: 10.1002/jcla.24328. Epub 2022 Mar 29. J Clin Lab Anal. 2022. PMID: 35349744 Free PMC article.
-
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness.
Chattopadhyay A, Jailani AAK, Mandal B. Chattopadhyay A, et al. Vaccines (Basel). 2023 Aug 9;11(8):1347. doi: 10.3390/vaccines11081347. Vaccines (Basel). 2023. PMID: 37631915 Free PMC article. Review.
References
-
- Zaki AM, van Boheemen S, Bestebroer TM, et al.. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20 - PubMed
-
First report about the isolation of Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) in humans.
-
- WHO Middle East respiratory syndrome coronavirus. (MERS-CoV) - update. Available from: www.who.int/csr/don/2014_03_26/en/ [Last accessed 26 March 2014] - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources